Identification and characterization of cancer stem cells (CSCs) in gastric cancer are difficult owing to the lack of specific markers and consensus methods. In this study, we show that cells with the CD90 surface marker in gastric tumors could be enriched under non-adherent, serumfree and sphere-forming conditions. These CD90 þ cells possess a higher ability to initiate tumor in vivo and could re-establish the cellular hierarchy of tumors from singlecell implantation, demonstrating their self-renewal properties. Interestingly, higher proportion of CD90 þ cells correlates with higher in vivo tumorigenicity of gastric primary tumor models. In addition, it was found that ERBB2 was overexpressed in about 25% of the gastric primary tumor models, which correlates with the higher level of CD90 expression in these tumors. Trastuzumab (humanized anti-ERBB2 antibody) treatment of hightumorigenic gastric primary tumor models could reduce the CD90 þ population in tumor mass and suppress tumor growth when combined with traditional chemotherapy. Moreover, tumorigenicity of tumor cells could also be suppressed when trastuzumab treatment starts at the same time as cell implantation. Therefore, we have identified a CSC population in gastric primary tumors characterized by their CD90 phenotype. The finding that trastuzumab targets the CSC population in gastric tumors suggests that ERBB2 signaling has a role in maintaining CSC populations, thus contributing to carcinogenesis and tumor invasion. In conclusion, the results from this study provide new insights into the gastric tumorigenic process and offer potential implications for the development of anticancer drugs as well as therapeutic treatment of gastric cancers.
Identification and characterization of cancer stem cells (CSCs) in gastric cancer are difficult owing to the lack of specific markers and consensus methods. In this study, we show that cells with the CD90 surface marker in gastric tumors could be enriched under non-adherent, serumfree and sphere-forming conditions. These CD90 þ cells possess a higher ability to initiate tumor in vivo and could re-establish the cellular hierarchy of tumors from singlecell implantation, demonstrating their self-renewal properties. Interestingly, higher proportion of CD90 þ cells correlates with higher in vivo tumorigenicity of gastric primary tumor models. In addition, it was found that ERBB2 was overexpressed in about 25% of the gastric primary tumor models, which correlates with the higher level of CD90 expression in these tumors. Trastuzumab (humanized anti-ERBB2 antibody) treatment of hightumorigenic gastric primary tumor models could reduce the CD90 þ population in tumor mass and suppress tumor growth when combined with traditional chemotherapy. Moreover, tumorigenicity of tumor cells could also be suppressed when trastuzumab treatment starts at the same time as cell implantation. Therefore, we have identified a CSC population in gastric primary tumors characterized by their CD90 phenotype. The finding that trastuzumab targets the CSC population in gastric tumors suggests
Introduction
Cancer stem cells (CSCs) are generally considered 'cells within a tumor that possess the capacity for self-renewal and that can cause the heterogeneous lineages of cancer cells that constitute the tumor' (Clarke et al., 2006) . CSCs have been identified in many solid tumor types, including breast cancer, brain cancer, prostate cancer, melanoma, colon cancer, liver cancer, pancreatic cancer and head and neck cancer (Al-Hajj et al., 2003; Singh et al., 2004; Collins et al., 2005; Li et al., 2007; O/'Brien et al., 2007; Prince et al., 2007; Ricci-Vitiani et al., 2007) . CSCs are similar to normal adult stem cells to some extent in that they both contain self-renewal and differentiation properties. The stem cell-like phenotype of these cells is believed to help them escape conventional therapies (Reya et al., 2001; Lobo et al., 2007) . This could lead to disease relapse even when the bulk of the tumor mass is eradicated (Ma et al., 2007) .
Gastric cancer is the fourth most common cancer in the world, found predominantly in the Asian countries (Bowles and Benjamin, 2001; Jemal et al., 2008) . Although numerous studies have provided evidence for the involvement of human stem or progenitor cells in human carcinogenesis, few have been reported on either identification of CSCs in human gastric tumor specimens or isolation of such gastric cancer cells (Takaishi et al., 2008; Zou, 2008) . Interestingly, stem cell populations can be highly enriched with sphere cultures. Previously, it has been shown that neuro-sphere formation in vitro is useful for the isolation of neural stem cells (Reynolds and Weiss, 1992) . Up to date, CSCs have been isolated from several types of tumors, including breast and prostate cancers, by similar approaches (Dontu et al., 2003; Dubrovska et al., 2009) .
Published data have shown that both the cell of origin and the oncogenic transformations could contribute to different phenotypes of CSCs (Kelly and Gilliland, 2002; Jamieson et al., 2004) . One approach to identify shared CSC markers from the same tissue of origin is to focus on defined functions, such as in vivo tumorigenicity and self-renewal properties. CD90 (Thy-1) is a 25-to 37-kDa cell-surface-anchored glycoprotein (Rege and Hagood, 2006) . Its expression has been found in bone marrowderived mesenchymal stem cells (Dennis et al., 2007) , hepatic stem/progenitor cells (La´zaro et al., 2003; Dan et al., 2006; Herrera et al., 2006) , hematopoietic stem cells and keratinocytic stem cells (Nakamura et al., 2006; Araki et al., 2007; Haack-Sorensen et al., 2007) . It has also been identified in human liver CSCs, murine breast CSCs and primarily cultured CD133 þ glioblastoma CSCs (Liu et al., 2006; Cho et al., 2008; Yang et al., 2008) . CD90 was found to be expressed in 95% of clinical gastric tumor samples by immunohistochemical staining (Oikonomou et al., 2007) .
It has been shown that multiple pathways are involved in the self-renewal and tumor progression of CSCs, including Notch, Wnt, Hedgehog and phosphatidyl-inositol-3 kinase (PI3K) etc (Taipale and Beachy, 2001; Reya and Clevers, 2005; Farnie and Clarke, 2007; Dubrovska et al., 2009; Zhao et al., 2009) . The ERBB2 (HER2) gene is amplified in approximately 20-30% of human breast and gastric cancers, in which it is associated with aggressive disease and early development of metastasis (Slamon et al., 1989; Tanner et al., 2005; Yano et al., 2006) . A significant correlation between ERBB2 overexpression and expression of the stem cell marker ALDH1 has been found in a series of 491 breast cancer patients (Ginestier et al., 2007) . Furthermore, ERBB2 has been shown to have an important role in maintaining the CSC population in breast carcinomas (Korkaya et al., 2008; Wang et al., 2010) . Interestingly, overexpression of ERBB2 could increase the proportion of stem/progenitor cells in both normal and malignant mammary epithelial cells (Korkaya et al., 2008) .
In the present study, CD90 is identified as a CSC marker in gastric cancers based on functional selections. We show that a cell population with the CD90 phenotype is enriched in sphere-cultured cells from human gastric primary tumors. The CD90 þ cells bear self-renewal properties and abilities to establish a tumor hierarchy from single-cell implantation. Moreover, the expression of this CSC marker closely correlates with the in vivo tumorigenicity of the gastric primary tumor models. These findings suggest that CD90 could be used to identify and isolate the CSC population in human gastric tumors, and provide evidence for the 'cancer stem cell hypothesis'. In addition, our results indicate that ERBB2 is amplified and overexpressed in 75% of high-tumorigenic gastric primary tumor models with high expression of CD90. Treatment of highly tumorigenic gastric primary tumors with the humanized anti-ERBB2 antibody trastuzumab (herceptin) (Beuzeboc et al., 1999) could reduce the CD90 þ population in tumor mass and suppress tumor growth when combined with traditional chemotherapy. The tumorigenicity of tumor cells could also be suppressed when trastuzumab treatment starts at the same time as cell implantation. Our results show that trastuzumab targets the CSC population in gastric primary tumors, and support the hypothesis that ERBB2 signaling regulates the stem/progenitor cell population in gastric primary tumors.
Significance
Gastric cancer is the fourth most common form of cancer in the world. Few studies have been reported on either identification of CSCs in human gastric tumor specimens or isolation of such cells. In this study, we identified a CSC population in gastric primary tumor models characterized by their CD90 phenotype. These cells possess a higher ability to initiate tumor in vivo and could re-establish the cellular hierarchy of tumors from single-cell implantation, demonstrating their self-renewal properties. Furthermore, the maintenance of CD90 þ cell populations in gastric primary tumor models could be undermined by trastuzumab treatment in vivo. Thus, our study provided new ground for testing efficient anticancer therapies and drug candidates in gastric carcinomas.
Results
Identification of gastric primary tumor models of high tumorigenicity Both normal and neoplastic stem cells have abilities to self-renew and differentiate. Such abilities could be evaluated by serial transplant studies that enable the separation of cells bearing self-renewal ability from those capable of limited non-self-renewing cell divisions. In the present study, tumorigenicity is defined as the capability of a certain number of cells to form tumor nodules in immunodeficient mice within a given time interval. One golden criterion to demonstrate CSC properties is to assess their in vivo tumorigenicity. Therefore, we decided to test the tumorigenic potential of various gastric primary tumors in vivo.
After dissociation by enzymatic digestion, 1000 cells from xenografted primary tumor tissues were implanted onto nude mice. Tumor development was monitored twice a week, and tumor take rates have been summarized in Table 1 . Primary tumor models, from which 1000 isolated cells could establish tumor masses at 100% efficiency within 1 month, were designated as the high-tumorigenicity group. The others, from which 1000 dissociated cells could not develop tumors within 2 months, were designated as the low-tumorigenicity group. Among the 20 gastric primary tumor models tested, six fell into the low-tumorigenicity group, whereas four models were classified into the hightumorigenicity group (Table 1) . Low CHGA03 0/6 0/6 0/6 0/6 Low CHGA04 0/6 0/6 0/6 0/6 Low CHGA06 0/6 0/6 0/6 0/6 High CHGA07 6/6 2/6 6/6 6/6 High CHGA11 6/6 4/6 6/6 6/6 Low CHGA12 0/6 0/6 0/6 0/6 Low CHGA13 0/6 0/6 0/6 0/6 High CHGA20 6/6 4/6 6/6 5/6 Low CHGA21 0/6 0/6 0/6 0/6 High CHGA27 6/6 6/6 6/6 6/6 In addition, cells isolated from CHGA07 could establish primary cell cultures and sphere cultures in vitro, even after being passaged for several times. Thus, the CHGA07 primary tumor model was chosen to serve as a tool in subsequent studies to identify potential CSCs markers in gastric cancers.
Higher in vivo tumorigenicity of spheroids derived from primary tumor cells Cells, which could form non-attached spheroids under serum-free conditions, are considered as tumor-initiating cells with properties similar to those of stem cells (Dontu et al., 2003; Kondo et al., 2004; Chen et al., 2007) . The bulk population of cells isolated from CHGA07 tumors grew as attached epithelial cells under normal culture conditions using Dulbecco's modified Eagle's medium (DMEM)/F12 media supplemented with 10% fetal bovine serum. After dissociation and washing with serum-free medium, single cells from tumors were seeded with Endothelial Basal Medium-2 medium (Lonza) containing epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) supplements. CHGA07 tumor cells could form spheroids after 72 h of incubation (Supplementary Figure 2) . The spheres were dissociated into single cells and placed in sphere culture medium again. By this approach, the spheroids could be enriched and passed every 3-4 days for many generations.
To test whether tumor-initiating cells were enriched in sphere cultures, cancer cells ranging from 200 to 2 Â 10 5 , prepared either from primary or sphere cultures of CHGA07, were implanted onto nude BALB/c mice. Tumor formation in vivo was monitored and tumor sizes were measured twice a week. Overall, cells derived from CHGA07 sphere cell cultures could initiate tumor formation more efficiently than those derived from primary cell cultures ( Figure 1a 
Upregulated expression of stem cell-related markers in CHGA07 spheroids
In order to identify potential markers for CSCs in gastric cancers, the RNA levels of several potential stem cell-related markers in CHGA07 tumor cells, primary and sphere cultures were analyzed by quantitative PCR (qPCR). Interestingly, the expression of most potential stem cell-related markers tested decreased in primary cell culture when compared with the original tumor cells. However, the expression levels of those markers could be restored or further increased in sphere cell cultures. Among the potential markers significantly upregulated in the sphere cell cultures of CHGA07 compared with the primary cell cultures, the RNA levels of CD90, Oct4, Sox2, Notch1 and ALDH1 increased 102-, 53-, 3.6-, 103-and 6.1-fold, respectively ( Figure 2 ). However, there were also some markers whose expression did not change much in sphere or primary cell cultures compared with the original tumor cells (for example, CD133).
Correlation of CD90 expression levels with in vivo tumorigenicity of gastric primary tumor models Initially, we found that the CD90 þ population was enriched in the sphere cultures and decreased in the primary cell cultures derived from CHGA07. Cells isolated from CHGA07 primary tumors, primary or sphere cultures were subjected to fluorescence-activated cell sorting (FACS) analysis to identify the CD90 þ cell population. As shown in Supplementary Table 1, the CD90 þ population consisted of about 21.5±5.4% (n ¼ 3) of the whole cell population directly dissociated from CHGA07 tumors. It was enriched in sphere culture (52.2±3.8%, n ¼ 3) and decreased in primary cell culture (4.0±0.7%, n ¼ 3), which is consistent with RNA expression levels ( Figure 1) . The CD90 RNA level was then examined across all high-and low-tumorigenicity primary tumor models. It was found that CD90 expression was significantly higher in the high-tumorigenicity group than that in the lowtumorigenicity group (Figure 3a , P ¼ 0.002, unpaired t-test). Next, we examined the percentages of CD90 þ cell population in all high-tumorigenicity and lowtumorigenicity gastric primary tumor models by FACS analysis. Consistent with RNA expression levels, our results revealed that percentages of CD90 þ population were also significantly higher in the high-tumorigenicity group than in the low-tumorigenicity group (Figure 3b  and Supplementary Table 1 ; Po0.0001, unpaired t-test). This indicated that the proportion of cells expressing the CD90 surface marker in whole primary tumors also correlates with the in vivo tumorigenicity of different gastric primary tumor models.
Enrichment of gastric CSCs in the CD90
þ cell population To compare the tumorigenicity of CD90 þ versus CD90 À cells from different primary tumor models, CD90 þ and CD90 À cells were sorted from directly dissociated tumor cells of CHGA07, CHGA11 (high-tumorigenicity group) and CHGA13 (low-tumorigenicity group), and implanted onto nude mice ( Figure 4a ). Generally, the CD90 þ cell population showed higher tumorigenicity than the CD90 À cells regardless of the tumorigenicity group from which they were originally isolated. The CD90 þ cells from the CHGA07 and CHGA11 tumor cells showed similar tumor take rates. About 80-90% of single-cell implantations could develop tumors by 2 months (Figure 4b ). Although the CD90 þ cells from CHGA13 showed higher tumor take rates than unsorted tumor cells and the CD90 À population, their tumorigenicity was still lower than that of the CD90 þ cells from CHGA07 and CHGA11. We also tested whether the CD90 þ and/or the CD90 À cells from xenografts derived from CD90 þ cells were able to secondarily transplant gastric tumors in vivo. Similar results as the tumor implantations from isolated tumor cells sorted from the primary tumors were observed. Histopathological analysis revealed that tumors derived from single Figure 3) . These results indicated that CSCs were enriched in CD90 þ cell population and supported the notion that CD90 could serve as a potential marker for CSCs in gastric primary tumors. However, there could be multiple markers for gastric CSCs and different CSCs might contribute together to the establishment and development of primary gastric tumor in vivo.
Correlation of ERBB2 amplification and overexpression with CD90 expression The ERBB2 gene, which has been implicated in mammary tumorigenesis and metastasis, is amplified in about 25% of our gastric primary tumor models. ERBB2 copy numbers in gastric primary tumor models were measured by quantitative PCR. Three out of four high-tumorigenicity models (CHGA07, CHGA11 and CHGA27) turned out to have ERBB2 gene amplification (450-fold; Supplementary Table 1) . By contrast, no low-tumorigenicity tumor models contain ERBB2 amplification in their genomes. As for protein levels, all three ERBB2-amplified high-tumorigenic models showed high levels of ERBB2 and phospho-ERBB2 proteins. Likewise, all primary tumor models with low tumorigenicity showed low levels of ERBB2 protein ( Figure 5 ). Moreover, it was found that the RNA expression levels of ERBB2 were significantly higher in the high-tumorigenicity group compared with that in the low-tumorigenicity group (P ¼ 0.03, unpaired t-test; Supplementary Figure 4) . The RNA expression levels of ERBB2 were closely correlated with those of CD90 (R-squared ¼ 0.68 by Pearson correlation). Figure 3 CD90 RNA expression levels in high and low tumorigenic gastric primary tumor model. (a) CD90 RNA levels were significantly higher in the high-tumorigenicity group than those in the low-tumorigenicity group (**P ¼ 0.002, unpaired t-test). All CD90 expression levels were calculated relatively to CHGA07 CD90 expression level, with the human GAPDH gene acting as an internal control. (b) The percentages of CD90 þ population were significantly higher in the high-tumorigenicity group than in the low-tumorigenicity group (**Po0.0001, unpaired t-test). Elimination of CSC population in primary gastric tumors by trastuzumab treatment To test whether ERBB2 contributes to the maintenance of the CSC population in gastric primary tumors, CHGA07, CHGA20 and CHGA27 primary tumors were treated with FOLFOX chemotherapeutic reagents, trastuzumab or a combination therapy of FOLFOX and trastuzumab for 3 weeks in vivo. All these three gastric tumor models are high-tumorigenic. Among them, CHGA07 and CHGA27 are ERBB2-amplied models, whereas CHGA20 is not. Our results indicated that CHGA07 gastric primary tumors were resistant to FOLFOX chemotherapeutic treatment or trastuzumab treatment alone (Figure 6a) . Neither of the two treatment groups showed significant differences in CHGA07 tumor growth when compared with the vehicle group. However, tumor growth in the combination therapy group was significantly suppressed (twoway analysis of variance (ANOVA) with Bonferroni post-test). Furthermore, the CD90 þ population in the primary tumors decreased to less than 5.0% in both trastuzumab alone and in the combination therapy groups. Whereas, in the vehicle-and FOLFOX alonetreated groups, the percentages of CD90 þ population were similar to those of the original CHGA07 primary tumors ( Figure 6b) .
As for the CHGA27 primary tumor model, tumor growth was significantly suppressed in all three treatment groups (two-way ANOVA with Bonferroni posttest) (Figure 6c ). An increased percentage of CD90 þ cell population was observed in the FOLFOX treatment group when compared with the vehicle group or the original CHGA27 primary tumors. Similar to results obtained from the CHGA07 model, the CD90 þ populations in the CHGA27 primary tumors were reduced to about 5.6% and 3.0% in the trastuzumab and the combination therapy groups, respectively. Thus, in both chemotherapy-resistant and -sensitive ERBB2-amplified gastric tumor models, trastuzumab treatment could reduce the CD90 þ population in the whole tumor mass. It was also worth noting that, although chemotherapeutic reagents showed some inhibitory effects on tumor growth in the sensitive model, it actually increased the potential CSC population percentage in the remaining tumors.
Although without ERBB2 amplification, the tumor growth of CHGA20 was also significantly suppressed in the combination therapy group by 45.4% after 21 days of treatment (two-way ANOVA with Bonferroni posttest) (Figure 6e ). Moreover, trastuzumab treatment could still reduce the CD90 þ population in the CHGA20 primary tumors, although not as significantly as in CHGA07 and CHGA27 (Figure 6f ).
Suppression of tumorigenicity by trastuzumab prophylactic treatment
To further confirm that trastuzumab targets the CSC population specifically, we further analyzed its in vivo effects on the tumorigenicity of isolated CHGA07 tumor cells. Treatment with FOLFOX and trastuzumab alone or by combination therapy was started at the same time when 1000 CHGA07 tumor cells were implanted onto nude mice. Consistent with our previous observation, 1000 CHGA07 tumor cells could initiate tumor at 100% efficiency in the vehicle group within 4 weeks ( Table 1 and Figure 7 ). In the FOLFOX group, 7 out 8 mice developed tumor within 4 weeks of treatment. By contrast, only one mouse was observed with tumor development in both the trastuzumab alone and the combination therapy group (Figure 7 ). These data suggested that trastuzumab suppressed the tumorigenicity of CHGA07 primary tumor cells in vivo dramatically when administered at the same time as tumor inoculation, probably by targeting the CSC populations. Therefore, our result implied that ERBB2 signaling might contribute to the maintenance of the CSC population in gastric primary tumors, which was consistent with previous reports, in which a similar role of ERBB2 in breast cancers was reported (Korkaya et al., 2008) .
Discussion
It is generally believed that the CSC populations share certain common properties, such as self-renewal, multipotency and tumorigenicity. Different mechanisms might be involved to maintain and develop such populations as shown in previous studies. For example, multiple CSC markers have been identified for tumors originated from different tissues or even for the same type of cancers (such as CD44 for breast cancers and CD133 for glioblastoma). Thus, it could have broad implications if one can identify common markers or pathways that are shared by several primary gastric tumors.
In this study, we aim to identify, isolate and characterize the CSC population in gastric carcinomas based on functional selections in vitro as well as in vivo, and to discover possible mechanisms involved in maintaining such a population in gastric cancers. Although concerns remain in that xenotransplantation may change the properties of normal and cancer cells, the in vivo assay is still the gold standard for testing the functional properties of stem cells. Whereas previous studies mainly isolated CSC-like cell populations from established gastric cell lines (Fukuda et al., 2009) Figure 5 ERBB2 was highly expressed in high-tumorigenicity gastric primary tumor models. ERBB2 and phospho-ERBB2 proteins were highly expressed in three high-tumorigenic models as detected by western blotting. GAPDH served as a reference control.
Trastuzumab targets the CSC population in gastric tumors J Jiang et al strategy is likely to closely mimic the original status of patient tumor samples and offer more heterogeneity of tumor cell populations. Instead of selecting cells based on speculated markers, which could be biased, we isolated and enriched the CSC-like cell population by functional selection through sphere cultures in vitro and tumor growth in vivo. Subsequently, we focus on the isolated CSC-like cells to identify markers and to investigate the underlying mechanisms of regulating such cells. Therefore, this strategy should offer a better opportunity to capture gastric CSCs and reveal their defining features mostly resembling their status in cancer patients.
In this study, we have identified CD90 as a potential marker for gastric CSCs. Initially, it was found that tumor-initiating cells were enriched in CHGA07 primary tumor cells grown under sphere conditions. A panel of stem cell-related genes was upregulated in sphere-cultured cells as compared with monolayercultured cells, including CD90, Oct4, Sox2, Notch1 and ALDH1. Oct4 and Sox2 are known embryonic stem cell factors essential for pluripotency and self-renewal of embryonic stem cells. Expression of these factors was found in many cancers and correlates with the histological grade of the tumors and the survival of the patients ( þ population (43.3 ± 0.4%) in the CHGA27 tumor mass, whereas trastuzumab significantly reduced the CD90 þ population in either the single (5.6 ± 1.0%) or the combination treatment group (3.0 ± 0.2%) when compared with the vehicle group (28.8 ± 1.3%) (unpaired t-test, **Po0.01). (e) Growth of CHGA20 was resistant to FOLFOX treatment or trastuzumab alone, but was sensitive to combination therapy of trastuzumab plus FOLFOX (**, two-way ANOVA with Bonferroni post-test). (f) Trastuzumab significantly reduced the CD90 þ population in either the single (20.3±1.8%) or the combination treatment group (18.6±1.0%) when compared with the vehicle group (27.2 ± 0.9%) (unpaired t-test, **Po0.01). FOLFOX chemotherapy treatment has no effects on the CD90 þ population (29.7 ± 1.5%).
Trastuzumab targets the CSC population in gastric tumors J Jiang et al 2006; Spisek et al., 2007; Wang et al., 2009) . Several studies have also identified Notch1 and ALDH1 as markers in both normal and malignant stem and progenitor cells (Dontu et al., 2004; Matsui et al., 2004; Ginestier et al., 2007) . Yang et al. (2008) first suggested CD90 to be a potential marker for liver CSCs. Interestingly, in addition to CD90 being highly enriched in cells cultured under sphere conditions, the percentage of CD90 þ cells in the population correlated closely with the tumorigenicity of the gastric primary tumor models. CD90 þ cells isolated from either high-or low-tumorigenicity tumor models showed higher tumorigenicity than CD90 À cells. Moreover, even a single CD90 þ cell could re-establish the tumor cell hierarchy in BALB/c nude mice, and tumors derived from CD90 þ cells are composed of both CD90 þ and CD90 À populations, which recapitulates the initial tumor phenotype. Together, these data provide evidence of the tumorigenicity and self-renewal properties of the CD90 þ cells in human gastric cancers and further support the notion that CD90 could serve as a marker for gastric CSCs. CD90 þ cells isolated from CHGA07 tumors, spheres and primary cultures bear similar tumorigenicity in vivo (unpublished data). Although in vitro monolayer culture reduced the CSC percentages in whole cell populations, the remaining CSCs in monolayer cultured cells still hold self-renewal properties similar to their counterparts in tumors or sphere-cultured cells. However, it is interesting to note that the CD90 þ cells isolated from CHGA13 bear relatively lower tumorigenicity than those from the CHGA07 and CHGA11 xenografted tumors. This suggests that CD90 may not be the single marker representing the CSCs of all gastric cancers, owing to the heterogeneity of the gastric cancers, as well as antecede evidence from other studies (Bowles and Benjamin, 2001; Takaishi et al., 2008) . A similar multimarker hypothesis has been suggested for CSCs in breast, liver and pancreatic cancers (Al-Hajj et al., 2003; Li et al., 2007; Yang et al., 2008) . ERBB2 overexpression could also contribute to the difference in the tumorigenicity of the CD90 þ cells isolated from different primary tumor models. Previously, it was shown that overexpression of ERBB2 not only increased the CSC population but also enhanced tumorigenicity within this population (Korkaya et al., 2008) . CD90 À cells showed lower tumorigenicity than CD90 þ and unsorted tumor cells, but could still form tumors when enough CD90
À cells were implanted. There are several possible explanations for this phenomenon. First, it is possible that during FACS sorting, a few CD90 þ cells might not be stained well by antibodies and therefore could contaminate the CD90 À populations. Second, there might be different CSC populations existing in gastric tumors, which are CD90
À and could synergistically contribute to tumor progression and metastasis. Further experiment investigating the relationship between CD90 and other well-characterized CSC makers such as CD44, CD133 and ALDH1 etc in solid tumors would be beneficial to elucidate the hypothesis that multiple CSC types exist in a tumor. Finally, it is also possible that a new tumorigenic progeny could reacquire stem cell properties under certain conditions. Such reprogramming or de-differentiation might occur more readily in an abnormal tumor cell than in a healthy cell as shown by reprogramming differentiated cells to a stem cell-like state by using defined transcription factors (Takahashi and Yamanaka, 2006; Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007) .
Initially, it was believed that CSCs only comprise a small fraction in whole tumor cell populations, such as reported in solid and haematopoietic cancers (Al-Hajj et al., 2003; Jamieson et al., 2004; Singh et al., 2004; Dalerba et al., 2007; O/'Brien et al., 2007) . Recent reports, based on transplantation of a broad spectrum of both primary and xenografted melanomas, contradict those conclusions (Quintana et al., 2008; Boiko et al., 2010) . In the study by Boiko et al., melanoma tumor stem cells were isolated using neural crest nerve growth factor receptor CD271, comprising between 2.5 and 41% (mean ¼ 16.7%) of the surgical patient melanoma samples and 6.4 and 75.3% (mean ¼ 26.3%) in xenografted tumors. Our results here show that CD90 þ characterized gastric CSCs comprise less than 4% of the total cell populations in low-tumorigenic gastric tumors, but comprise 21.5-36.3% in high-tumorigenic gastric tumors. The fact that CD90 þ cell populations reduce to only about 4% in CHGA07 monolayercultured cells as compared with 21.5% in xenografted CHGA07 tumors suggests that CSCs populations undergo differentiation and progression under in vitro culturing conditions, which leads to the loss of their CSCs properties. This interesting finding may possibly offer an explanation for why researchers were only able to identify rare CSC population in established cancer cell lines (Dubrovska et al., 2009; Fukuda et Trastuzumab targets the CSC population in gastric tumors J Jiang et al that our methods to establish primary tumor models might already allow the in vivo selection of aggressive and highly tumorigenic tumor subsets during tumor establishment. Thus, the CD90 þ population potentially could be lower in clinical samples. In addition, previous study shows that monoclonal anti-Thy-1.1 (CD90) antibodies suppressed the dissemination of Thy-1.1-positive murine leukemia cells and cured a significant proportion of mice (Bernstein et al., 1980; Seeger et al., 1982) . These findings clearly show that CD90 potentially has a value as a target for immunotherapy.
ERBB2 amplification is found in 20-30% of gastric carcinomas and is reported to be significantly associated with shorter survival of cancer patients (Tanner et al., 2005; Yano et al., 2006; Marx et al., 2009) . How ERBB2 signaling affects tumor growth, invasion and metastasis is still not clear. The fact that 3 out of 4 of our hightumorigenicity gastric primary tumor models bear ERBB2 amplification in their genomes leads to our hypothesis that ERBB2 signaling might contribute to the maintenance of the CSC population in gastric carcinomas. Both the CHGA07 and the CHGA27 primary tumor model are of the high-tumorigenicity group and bear ERBB2 amplification. They responded differently to FOLFOX chemotherapy in vivo (Figures  6a and c) . CHGA07 is FOLFOX-resistant, whereas CHGA27 is FOLFOX-sensitive. Interestingly, chemotherapeutic treatment does not change the percentage of the CD90 þ cell population in the resistant model CHGA07. Yet it does enrich the CD90 þ cell population in the sensitive model CHGA27. This increase of CD90 þ cells in the remaining tumor mass is in concordance with previous studies on breast cancers showing that tumor-initiating cells were enriched after conventional treatments (Li et al., 2008; Creighton et al., 2009) . On the other hand, trastuzumab treatment could significantly reduce the CD90 þ cell population in the tumor mass of both models tested (Figures 6b and d) . The effects of trastuzumab treatment were further elucidated by testing its impact on the tumorigenicity of isolated tumor cells in vivo. As the model we chose (CHGA07) was resistant to FOLFOX chemotherapy in vivo (Figure 6a) , it was not surprising that FOLFOX treatment alone could not effectively prevent tumor development from implantation with 1000 tumor cells. By contrast, in both the trastuzumab alone and the combination therapy group, only 1 out of 8 mice developed tumor after 4 weeks of dosing (Figure 7) . Our results suggest that the effectiveness of trastuzumab may be directly related to its effects on the CSC population, which is consistent with previous studies on mammary CSCs (Burstein et al., 2001; Korkaya et al., 2008; Wang et al., 2010) . The observation of no significant difference in tumor growth between the trastuzumab group and the vehicle group of CHGA07 could be due to other factors, such as limited growth potential of the remaining tumor cells and short observation period.
Clinically, it has been noticed that some breast cancer patients with normal ERBB2 gene expression may benefit from trastuzumab therapy (Paik et al., 2008; Riley et al., 2010) . The fact trastuzumab could reduce the CD90 þ cell population in ERBB2-non-amplified CHGA20 primary tumors does support this clinical observation. By eradicating CSCs, trastuzumab might be used to treat patients diagnosed with ERBB2-nonamplified breast and gastric cancer. More research is needed before people fully understand the underlying mechanism of this ERBB2-targeted therapy (Korkaya et al., 2008) .
The CSC hypothesis implies that targeting markers or pathways specific for CSCs is crucial for curative therapies in cancer patients. In order to further study the potential pathways affected by trastuzumab, we performed microarray experiments on gastric models subjected to efficacy studies in vivo. The differentially expressed gene sets associated with trastuzumab treatment showed significant enrichment in protein metabolism, RNA processing and DNA repair. These findings are consistent with previous studies conducted on breast cancer cell lines (Kauraniemi et al., 2003) . Furthermore, in one of the models (CHGA07) the cell adhesion pathway was also enriched significantly. The regulated genes include factors of the cadherin and claudin families (data not shown).
Taken together, our study here provides evidence for the existence of gastric CSCs, which could be marked by a CD90 þ phenotype. Treatment of high-tumorigenic gastric primary tumors with trastuzumab could reduce such a population in vivo. This offers new insights into research of gastric carcinogenesis and provides new ground for testing of efficient cancer therapies and candidate anticancer drugs in clinic.
Materials and methods
Establishment of gastric primary tumor models Tumor specimens were provided by local hospitals after obtaining informed consent. Experiments were conducted on female BALB/c nude mice (from SLACCAS) aged 4-6 weeks old. The animals were housed in an specific pathogen free (SPF) animal facility in accordance with the Guide for Care and Use of Laboratory Animals and the regulations of the Institutional Animal Care and Use Committee. Freshly collected tumor samples were cut into small pieces and transplanted subcutaneously to BALB/c nude mice. Once a primary tumor model was able to be passaged to the second generation, it would be designated as an established mode. All the primary tumors used in this study are over passage-3, which will not change much when passaged afterwards.
Sphere cell cultures
For sphere cultures, single dissociated cells from a gastric primary tumor model were plated at a concentration of 5000 cells/ml onto low-attachment dishes with an ultralowattachment surface. Serum-free epithelial basal medium (EBM-2; Lonza, Walkersville, MD, USA), supplemented with 4 mg/ml insulin (Sigma, St Louis, MO, USA), B27, 20 ng/ml EGF and 20 ng/ml basic fibroblast growth factor (Invitrogen, Carlsbad, CA, USA), was used to culture those cells in vitro. Spheres were collected after 4 days and dissociated with accutase (Millipore, Temecula, CA, USA). The cells obtained from dissociation were sieved through a 40-mm filter and re-seeded with sphere culture medium to expand. The sphere cultures obtained from CHGA07 could be expanded for over five passages without obvious change in growth behavior.
Tumor digestion
Xenografted tumor tissues were collected aseptically at necropsy from gastric tumor xenograft mice, rinsed in DMEM tissue culture media and minced to very small tissue clumps, and treated with 0.4 ml of collagenase (2000 U/ml) and 4 ml of accutase for 1.5 h at room temperature and 1 h at 37 1C to dissociate into single cells. The dissociated cells were passed through 40-mm filters (Becton Dickinson, Bedford, MA, USA) and treated with LCK buffer to eliminate erythrocytes. The cells were then washed twice with DMEM and stained for flow cytometry or injected into mice as whole-tumor single-cell suspensions.
Analysis and cell separation by flow cytometry Single-cell suspensions obtained from tumor samples or cell cultures were first subjected to treatment using the CELLection Biotin Binder kit (Invitrogen) and biotin-labeled, antimouse CD45 and H-2Kd antibodies (Biolegend, San Diego, CA, USA), or stained with Cy5.5-labeled, anti-mouse CD45 and H-2Kd antibodies (Biolegend), to exclude mouse lineage. mLin
) cells were then stained with a fluorescein isothiocyanate mouse anti-human CD90 antibody (BD Pharmingen, San Diego, CA, USA) and analyzed by FACS. 7-AAD (7-Aminoactinomycin D) was used to exclude non-viable cells. Flow cytometric analysis and cell sorting were performed on a MoFlo XDP (Beckman Coulter, Miami, FL, USA), under 20 psi by using a 100-mm nozzle.
Single-cell suspension injections FACS-sorted tumor cells were counted and graded numbers of cells were suspended in a volume of 100 ml phosphate-buffered saline containing 50% standard matrigel (BD Pharmingen). The suspension was then injected intradermally by using 31-gauge insulin syringes (Becton Dickinson) onto the flank of 4-to 6-week-old BALB/c nude mice anaesthetized with isoflurane-O 2 .
For single-cell injections, cell suspensions were diluted with cold phosphate-buffered saline to about 1 cell/50 ml. A 50-ml volume of this diluted cell suspension was dispensed onto a 96-well plate. Wells containing single cell were identified with a microscope and the cells were mixed with Matrigel and injected onto nude mice.
Tumor measurement and endpoints
After tumors became palpable (over 50 mm 3 in size), they were measured in two dimensions by using calipers. Their volumes were calculated based on the modified ellipsoidal formula: tumor volume ¼ (length Â width 2 ) Â 0.5 (Euhus et al., 1986; Tomayko and Reynolds, 1989) . Endpoints for mice were when tumor sizes reached above 1500 mm 3 or the studies terminated.
Real-time, quantitative reverse transcriptase-PCR Total RNA and DNA were extracted from cells or tissues by using the Allprep DNA/RNA/Protein Mini kit (Qiagen, Valencia, CA, USA). RNA was resuspended in RNase-free water and DNA was dissolved in EB buffer (Qiagen). Firststrand cDNA was synthesized by using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen). Real-time quantitative was performed by using the first-strand cDNA for RNA expression or total DNA for DNA copy-number detection, using 250 nM forward and reverse primers, and the SYBR Green PCR master mix (Applied Biosystems, Carlsbad, CA, USA). The primer sequences and PCR conditions are summarized in Supplementary Table 2 . The reactions were performed by using the ABI 7900HT Fast Real-Time PCR (Applied Biosystems). Fluorescence signals were analyzed by using the SDS 2.3 software (Applied Biosystems). RNA expression levels were calculated as the relative expression ratio compared with human GAPDH. All ERBB2 copy numbers were calculated relatively to breast cancer cell line MDA-MB-231 ERBB2 copy numbers, with the human APP gene acting as an internal control.
Immunoblotting
Frozen tumor tissues were placed in the T-PER Protein Extraction Reagent (Thermo Scientific, Waltham, MA, USA) þ 1% Phosphatase Inhibitor Cocktail (Sigma) and homogenized for protein extraction. The protein extracts were combined with loading dye, boiled and loaded onto sodium dodecyl sulfate-polyacrylamide gels. Following electrophoresis, proteins were transferred onto nitrocellulose membranes (Pierce, Rockford, IL, USA) by using semidry Trans-Blot (Bio-Rad Laboratories, Hercules, CA, USA). The blots were first incubated in Tris-buffered saline (TBS) blocking buffer containing either 2% milk or 2% bovine serum albumin (for phosphospecific antibodies) for 1-2 h at room temperature and then with the respective primary antibodies diluted in TBST (Tris-buffered saline Tween-20, containing 0.1% Tween-20 and 2% bovine serum albumin) overnight at 4 1C. Subsequently, the blots were washed and incubated with the appropriate secondary antibodies (GE Healthcare, Piscataway, NJ, USA) in TBST and detected by using the ECL Plus Western Blotting Detection System (GE Healthcare). Antibodies to human ERBB2 (Neomarker, Fremont, CA, USA; B-2 Ab-17), phospho-ERBB2 (Tyr1221/1222) (CST, 6B12; #2243) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (CST, 14C10; #2118) were applied.
FOLFOX chemotherapeutic and trastuzumab treatment of nude mice bearing xenografted tumors Both 5-FU (fluorouracil) and calcium folinate were prepared separately in 0.9% NaCl as 1.5-mg/ml and 0.5-mg/ml solutions, respectively, and delivered through intraperitoneal injection at a dose of 15 mg/kg and 5 mg/kg each once a day. Calcium folinate was injected 15-20 min before 5-FU injection. Oxaliplatin was prepared in H 2 O as a 0.5-mg/ml solution and delivered through intraperitoneal injection at a dose of 5 mg/kg once a week. Each vial of trastuzumab powder was reconstituted by adding Bacteriostatic Water for Injection containing 1.1% benzyl alcohol to yield a 22-mg/ml multi-dose stock solution. The working solution of trastuzumab was prepared by diluting the stocking solution with saline to deliver through intraperitoneal injection at a dose of 20 mg/kg twice a week.
The effect of drug treatment was analyzed by comparing the mean tumor volumes between the groups as a function of time. Mean tumor growth curves, with s.e.m., were plotted by using Prism 5 (GraphPad, La Jolla, CA, USA). Two-way ANOVA with Bonferroni post-test was used to calculate the P-value in predicting any significant difference (Po0.05).
